Search
Triethylenetetramine
go.drugbank.com/drugs/DB06824ApprovedInvestigational[A19333] Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease,[A19334] TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and … Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, [spermidine] and [spermine].
Categories: Compounds used in a research, industrial, or household settingGemfibrozil
go.drugbank.com/drugs/DB01241ApprovedInvestigational[L8525] Gemfibrozil was granted FDA approval on 21 December 1981.[L8525] … Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.
Products: GEMFIBROZIL DOC GENERICIBelatacept
go.drugbank.com/drugs/DB06681ApprovedInvestigationalStructurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. … FDA approved on June 15, 2011.
AZD0947
go.drugbank.com/drugs/DB04848ExperimentalAs of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline. … AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.
Isavuconazole
go.drugbank.com/drugs/DB11633ApprovedInvestigationalResistance to isavuconazole has been associated with the mutation in the target gene CYP51 [FDA Label]. … Cross-resistance between isavuconazole and other azoles was also proposed although the clinical relevance is unclear [FDA Label].
Darbepoetin alfa
go.drugbank.com/drugs/DB00012ApprovedInvestigationalHuman erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Masitinib
go.drugbank.com/drugs/DB11526InvestigationalVet approvedMasitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in dogs. It has been available in Europe since 2009, under the brand name Masivet.
LErafAON
go.drugbank.com/drugs/DB04973InvestigationalPhase I/II trials commenced in March 2001 and were ongoing as of June 2003.
Thonzylamine
go.drugbank.com/drugs/DB11235ApprovedThonzylamine is an antihistamine and anticholinergic drug. It is available as combination products with DB04837 or DB00388 for temporary relief of symptoms of common cold, hay fever (allergic rhinitis) or other upper respiratory allergies.
Mixtures: Poly-Hist DM